Metabolic dysfunction-associated steatohepatitis, or MASH, is a progressive liver condition driven by insulin resistance and metabolic risk factors. Medical professionals utilize imaging tests, blood work, and metabolic history to distinguish MASH from simpler fat buildup. While many patients feel fine, the disease carries a risk of fibrosis and, in some cases, cirrhosis. Clinicians stress that the condition is serious even without symptoms, and they recommend a mix of lifestyle changes and medication to halt progression.
Understanding the diagnosis and risk factors
Healthcare providers look for specific signs when diagnosing MASLD or its more severe form, MASH. The presence of liver steatosis on imaging, raised liver enzymes, or metabolic conditions like diabetes and hypertension often points to the disease. A clinician explained that MASH represents a more severe version of MASLD and may include reversible scarring. Risk increases with a high body mass index, abnormal cholesterol, and insulin resistance. Insulin resistance is frequently identified as the underlying cause of the disease’s development.
The progression timeline helps patients understand the urgency. It typically takes six to ten years to move through each stage of fibrosis, with cirrhosis potentially developing ten to twenty years after diagnosis. Up to 20% of patients with MASH eventually develop cirrhosis, which brings an associated risk of liver cancer. Despite these risks, the clinician emphasized that the condition is not life-threatening in its early stages, though it requires active management.
Reversing liver damage through weight loss and medication
Weight loss is the most effective intervention for reversing MASH and early fibrosis. A loss of more than 10% of body weight can improve the condition significantly. This target is difficult to reach through diet and exercise alone, so medical support is often necessary. GLP-1 medications, including tirzepatide, semaglutide, and liraglutide, are now approved for treating MASH, particularly when combined with obesity or diabetes. These drugs can improve steatohepatitis and potentially reduce fibrosis, though they carry side effects like gallstones and gastrointestinal issues.
For patients who do not tolerate GLP-1 medications or fail to lose weight with them, resmetirom offers an alternative. This drug is indicated for those with fibrosis who have not achieved sustained weight loss. While resmetirom can reverse fatty liver and fibrosis, it has a distinct side effect profile, including dizziness, itching, and potential liver injury. Both classes of medication require long-term use and depend on insurance coverage for accessibility.
Lifestyle changes and alcohol consumption guidelines
Lifestyle modifications serve as the first line of defense. Attempting a loss of 5% to 7% of body weight through diet and exercise is recommended before moving to pharmacologic therapy. Clinicians advise that this approach is effective for many patients, though it may not be sufficient for those with significant metabolic comorbidities. Physical activity and dietary adjustments work best when started early to prevent the disease from advancing.
Alcohol consumption does not need to be eliminated entirely. Guidelines suggest limiting intake to less than 14 drinks per week for men or less than 7 drinks per week for females, with similar limits on daily consumption. This moderation helps reduce additional stress on the liver while allowing patients to maintain social habits without severe restriction.
Monitoring Liver Health and Treatment Success
Patients on therapy for MASH require ongoing observation. Liver enzymes should be obtained every three to six months. If levels do not return to normal, further lab work is necessary. For those with biopsy-proven MASH who have not lost weight, elastography is recommended every three years. Patients who achieved weight loss and have normalized liver enzymes should undergo elastography every four years.
Monitoring progress and adjusting treatment plans
Doctors must carefully weigh the benefits and risks of medication. GLP-1 drugs require a long-term commitment, while resmetirom is limited by availability and cost. If a patient cannot afford or access these treatments, clinical management focuses on lifestyle changes and close monitoring of metabolic markers. The choice of therapy depends on individual health needs, insurance status, and the patient’s ability to adhere to a long-term regimen.